| Similar Articles |
|---|
 |
Chemistry World
July 11, 2012 |
Gsk Drug Shines in HIV Trial GlaxoSmithKline has announced good results for its HIV - Aids drug candidate dolutegravir, which has apparently outperformed Atripla tablets in Phase III.   |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
Chemistry World
January 11, 2016
Phillip Broadwith |
GSK's ViiV to buy HIV drugs from BMS Bristol-Myers Squibb has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology. |
The Motley Fool
July 13, 2004
Charly Travers |
With Pfizer Drug, HIV Retreats Pfizer's newest HIV treatment shows promise in a demanding market. |
The Motley Fool
June 21, 2011
Frank Vinluan |
GSK HIV Drug Pipeline Sees Boost as Partner Concert Steers to Clinical Trials GSK and Concert have a possible new treatment for HIV. |
The Motley Fool
July 27, 2011
Brian Orelli |
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
HIV: Better Combos and Classes Keep Coming The new class of integrase inhibitors is the main event on the calendar, as Gilead's elvitegravir and ViiV Healthcare's GSK 1349572 come online in 2013 and 2014, respectively. |
Chemistry World
April 25, 2014
Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
The Motley Fool
January 12, 2011
Brian Orelli |
Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up. |
BusinessWeek
September 2, 2010
Simeon Bennett |
David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS. |
The Motley Fool
February 18, 2010
Brian Orelli |
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. |
The Motley Fool
July 17, 2009
Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
The Motley Fool
June 30, 2009
Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool
July 31, 2009
Brian Orelli |
Can Emerging Markets Save Pharma? Probably not until after they emerge. |
The Motley Fool
February 3, 2010
Brian Orelli |
Wyeth Can't Save Pfizer Not much earnings growth, but the price is right. |
Chemistry World
November 28, 2012
Andrew Turley |
GSK expands in India and Nigeria GlaxoSmithKline is to spend 650 million pounds dramatically increasing its ownership of Indian and Nigerian subsidiaries. |
AskMen.com
Dave Golokhov |
Truvada With more and more studies finding successful AIDS prevention, it looks like we're getting closer to finding a cure. |
The Motley Fool
December 31, 2007
Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. |
The Motley Fool
April 3, 2008
Brian Lawler |
A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs. |
The Motley Fool
April 21, 2009
Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
The Motley Fool
January 6, 2010
Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool
December 21, 2004
Brian Gorman |
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. |
Salon.com
May 18, 2000
Sabin Russell |
The dream and the coming disaster AIDS threatens to ravage the hopes of South Africa's young democracy. Don't expect leaders to get excited because a few companies cut the cost of HIV drugs. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
BusinessWeek
January 29, 2007
Kerry Capell |
GlaxoSmithKline: Getting AIDS Drugs To More Sick People GlaxoSmithKline sells 90% of its vaccines, in volume terms, at not-for-profit prices to customers in the developing world. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
June 10, 2014
Anthony King |
Drug giants settle mismarketing lawsuits Pfizer and GlaxoSmithKline recently agreed to separate settlements over allegations of mismarketing drugs in the US. |
Popular Mechanics
December 1, 2006
Ben Harder |
Fighting HIV by Building a New Killer In the fight to find a cure for AIDS, researchers have invented a viral double agent on a mission to seek out where HIV hides. |
The Motley Fool
December 5, 2011
Alexander Crawford |
Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies Do you think these companies will contribute to a cure? |
The Motley Fool
January 27, 2010
Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. |
BusinessWeek
August 5, 2010
Bennett & Randall |
AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries. |
Salon.com
July 28, 2000
Kate Scanell |
Contributing to genocide By giving HIV deniers a global platform, South African President Mbeki has put countless lives at risk. |
D-Lib
October 2006
Judith M. Panitch |
Digital Collections at the University Library, University of North Carolina at Chapel Hill The University Library at the University of North Carolina at Chapel Hill is aggressively expanding its digital library program. |
Chemistry World
April 19, 2013
Phillip Broadwith |
Objections raised to GSK pay-for-delay deals The UK Office of Fair Trading has said that GlaxoSmithKline's deals to delay generic drugs infringed competition laws. |
Chemistry World
November 25, 2013
Phillip Broadwith |
Pfizer teams up with GSK in cancer drug trial Pfizer and GlaxoSmithKline have agreed to run a joint clinical trial to test a combination of Pfizer's candidate molecule palbociclib with GSK's approved drug Mekinist (trametinib) for advanced or metastatic melanoma. |
Salon.com
May 8, 2001
Daryl Lindsey |
The "Joe Camel" ads of AIDS? The FDA says ads for drugs to suppress HIV are making false promises, and could be contributing to an epidemic of unsafe sex... |
Chemistry World
July 11, 2012
Ling Wang |
China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances. |
The Motley Fool
July 12, 2011
Tracy Staton |
Gilead First to Jump Into AIDS Patent Pool Gilead Sciences has broken the ice on the AIDS drug patent pool. |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
The Motley Fool
April 15, 2011
Frank Vinluan |
GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands." |
Salon.com
December 1, 2000
Fiona Morgan |
It's World AIDS Day ... again Americans with insurance now improve with new drugs, but the disease is on a rampage across the rest of the world... |
The Motley Fool
November 29, 2010
Brian Orelli |
Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily. |
IDB America
September 2001
Joanne Nanton |
HIV/AIDS clouds the Caribbean A new joint effort by the nations of the Caribbean Community could help to contain the most serious AIDS crisis outside of Africa... |
The Motley Fool
March 29, 2010
Brian Orelli |
5 Drugmakers Producing Cash for You Take greenbacks over earnings any day. |
Scientific American
October 2008
John Rennie |
Hope and the Fight against HIV The battle must continue, even if 25 years of research have disappointed. |
American Journal of Nursing
March 2010
David E. Vance |
Aging with HIV: Clinical Considerations for an Emerging Population Since the advent of highly active antiretroviral therapy, HIV infection has become a chronic, albeit life-threatening, condition that can be managed; therefore, more and more people are growing older with HIV. |
The Motley Fool
September 20, 2011
Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
Salon.com
July 17, 2000
Nina Teicholz |
When drugs take a holiday Could taking a break from protease inhibitors be the secret to treating AIDS? A new case of a 40-year-old man in Philadelphia shows it's possible. |
